GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Five Prime Therapeutics Inc (NAS:FPRX) » Definitions » E10

Five Prime Therapeutics (Five Prime Therapeutics) E10 : $-1.92 (As of Dec. 2020)


View and export this data going back to 2013. Start your Free Trial

What is Five Prime Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Five Prime Therapeutics's adjusted earnings per share data for the fiscal year that ended in Dec. 2020 was $-2.290. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.92 for the trailing ten years ended in Dec. 2020.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-05-06), Five Prime Therapeutics's current stock price is $ 38.00. Five Prime Therapeutics's E10 for the fiscal year that ended in Dec. 2020 was $-1.92. Five Prime Therapeutics's Shiller PE Ratio of today is .


Five Prime Therapeutics E10 Historical Data

The historical data trend for Five Prime Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Five Prime Therapeutics E10 Chart

Five Prime Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -1.82 -1.92

Five Prime Therapeutics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.82 - - - -1.92

Competitive Comparison of Five Prime Therapeutics's E10

For the Biotechnology subindustry, Five Prime Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Five Prime Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Five Prime Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Five Prime Therapeutics's Shiller PE Ratio falls into.



Five Prime Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Five Prime Therapeutics's adjusted earnings per share data for the fiscal year that ended in Dec. 2020 was:

Adj_EPS=Earnings per Share (Diluted) /CPI of Dec. 2020 (Change)*Current CPI (Dec. 2020)
=-2.29/109.8968*109.8968
=-2.290

Current CPI (Dec. 2020) = 109.8968.

Five Prime Therapeutics Annual Data

per_share_eps CPI Adj_EPS
201112 0.079 95.213 0.091
201212 -2.471 96.871 -2.803
201312 -5.230 98.326 -5.845
201412 -1.790 99.070 -1.986
201512 9.230 99.792 10.165
201612 -2.440 101.863 -2.632
201712 -5.380 104.011 -5.684
201812 -4.130 105.998 -4.282
201912 -3.920 108.420 -3.973
202012 -2.290 109.897 -2.290

Add all the adjusted EPS together and divide 10 will get our e10.


Five Prime Therapeutics  (NAS:FPRX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Five Prime Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Five Prime Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Five Prime Therapeutics (Five Prime Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Five Prime Therapeutics Inc is a biotechnology company focused on discovering and developing protein therapeutics for diseases. The company's product candidates address patient populations for which therapies are still needed. It is focused on advancing its internal pipeline and retaining rights for products in targeted specialty markets. It also seeks to establish additional collaborations to supplement its internal development capabilities. These collaborations generate additional funding in order to further validate the company's technology. It has the following product in the pipeline: Cabiralizumab, FPA150, FPT155, and Bemarituzumab.
Executives
William R Ringo director
Biotechnology Value Fund L P 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
David White officer: See Remarks 4560 HORTON STREET EMERYVILLE CA 94608
Helen Louise Collins officer: EVP and Chief Medical Officer TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Garry A Nicholson director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451

Five Prime Therapeutics (Five Prime Therapeutics) Headlines

From GuruFocus

Five Prime Presents First Preclinical Data on Anti-CCR8 Antibody FPA157

By Business Wire Business Wire 11-12-2020

Five Prime Announces Closing of Upsized Public Offering of Common Stock

By Business Wire Business Wire 11-18-2020

Five Prime Announces Pricing of Upsized Public Offering of Common Stock

By Business Wire Business Wire 11-13-2020